Accelerated COVID-19 vaccine development: milestones, lessons, and prospects

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592 · cited 2×

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897

First case of 2019 novel coronavirus in the United States

Holshue, M. L., DeBolt, C., Lindquist, S., Lofy, K. H., Wiesman, J., Bruce, H., Spitters, C., Ericson, K., Wilkerson, S., Tural, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001191 · Cited by 6,030

Development of Virus-Like Particle Technology from Small Highly Symmetric to Large Complex Virus-Like Particle Structures

Pushko, P., Pumpens, P., & Grens, E. (2013) · Intervirology · doi:10.1159/000346773 · Cited by 5,975

mRNA vaccines — a new era in vaccinology

Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

Lopez Bernal, J., Andrews, N., Gower, C., Gallagher, E., Simmons, R., Thelwall, S., Stowe, J., Tessier, E., Groves, N., Dabrera, G., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108891 · Cited by 2,889

Effectiveness of COVID-19 vaccines against the B.1.617.2 variant

Bernal, J. L., Andrews, N., Gower, C., Gallagher, E., Simmons, R., Thelwall, S., Stowe, J., Tessier, E., Groves, N., Dabrera, G., et al. (2021) · doi:10.1101/2021.05.22.21257658 · Cited by 2,888 · cited 2×

Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis

Cromer, D., Steain, M., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Kent, S. J., Triccas, J. A., Khoury, D. S., & Davenport, M. P. (2022) · The Lancet Microbe · doi:10.1016/s2666-5247(21)00267-6 · Cited by 590

Harnessing the microbiome to prevent global biodiversity loss

Peixoto, R. S., Voolstra, C. R., Sweet, M. J., Duarte, C. M., Carvalho, S., Villela, H., Lunshof, J. E., Gram, L., Woodhams, D. C., Walter, J., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01173-1 · Cited by 284

COVID-19 Vaccination Hesitancy among Healthcare Workers—A Review

Peterson, C., Lee, B. D., & NUGENT, K. M. (2022) · Vaccines · doi:10.3390/vaccines10060948 · Cited by 232

Menstrual Symptoms After COVID-19 Vaccine: A Cross-Sectional Investigation in the MENA Region

Muhaidat, N., Alshrouf, M. A., Azzam, M., Karam, A. M., Al-Nazer, M., & Al-Ani, A. (2022) · International Journal of Women s Health · doi:10.2147/ijwh.s352167 · Cited by 168

Efficacy of SARS-CoV-2 vaccines and the dose–response relationship with three major antibodies: a systematic review and meta-analysis of randomised controlled trials

Yang, Z.-R., Jiang, Y.-W., Li, F.-X., Liu, D., Lin, T.-F., Zhao, Z.-Y., Wei, C., Jin, Q.-Y., Li, X.-M., Jia, Y.-X., et al. (2023) · The Lancet Microbe · doi:10.1016/s2666-5247(22)00390-1 · Cited by 138

A Systematic Review of Coronavirus Disease 2019 Vaccine Efficacy and Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Disease

Higdon, M. M., Wahl, B., Jones, C. B., Rosen, J. G., Truelove, S., Baidya, A., Nande, A., ShamaeiZadeh, P. A., Walter, K. K., Feikin, D. R., et al. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac138 · Cited by 133

A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice, rabbits and NHPs

Liu, Z., Zhou, J., Xu, W., Deng, W., Wang, Y., Wang, M., Wang, Q., Hsieh, M. K., Dong, J., Wang, X., et al. (2022) · Cell Research · doi:10.1038/s41422-022-00612-2 · Cited by 113

Delivering Pandemic Vaccines in 100 Days — What Will It Take?

Saville, M. K., Cramer, J. P., Downham, M., Hacker, A., Lurie, N., der Veken, L. V., Whelan, M., & Hatchett, R. J. (2022) · New England Journal of Medicine · doi:10.1056/nejmp2202669 · Cited by 92

In search of a pan-coronavirus vaccine: next-generation vaccine design and immune mechanisms

Cankat, S., Demael, M. U., & Swadling, L. (2023) · Cellular & Molecular Immunology · doi:10.1038/s41423-023-01116-8 · Cited by 84

Comparison of antibody and T cell responses elicited by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in healthy adult humans

Valyi-Nagy, I. T., Matula, Z., Gönczi, M., Tasnády, S., Bekő, G., Réti, M., Ajzner, É., & Uher, F. (2021) · GeroScience · doi:10.1007/s11357-021-00471-6 · Cited by 80

SARS-CoV-2 Infection: New Molecular, Phylogenetic, and Pathogenetic Insights. Efficacy of Current Vaccines and the Potential Risk of Variants

Rotondo, J. C., Martini, F., Maritati, M., Mazziotta, C., Mauro, G. D., Lanzillotti, C., Barp, N., Gallerani, A., Tognon, M. G., & Contini, C. (2021) · Viruses · doi:10.3390/v13091687 · Cited by 81

mRNA-LNP HIV-1 trimer boosters elicit precursors to broad neutralizing antibodies

Xie, Z., Lin, Y., Steichen, J. M., Ozorowski, G., Kratochvil, S., Ray, R., Torres, J. L., Liguori, A., Kalyuzhniy, O., Wang, X., et al. (2024) · Science · doi:10.1126/science.adk0582 · Cited by 71

Is vaccine confidence an unexpected victim of the COVID-19 pandemic?

Siani, A., & Tranter, A. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.10.061 · Cited by 67

Comparison of IgA, IgG, and Neutralizing Antibody Responses Following Immunization With Moderna, BioNTech, AstraZeneca, Sputnik-V, Johnson and Johnson, and Sinopharm’s COVID-19 Vaccines

Adjobimey, T., Meyer, J., Sollberg, L., Bawolt, M., Berens, C., Kovačević, P., Trudić, A., Parčina, M., & Hoerauf, A. M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.917905 · Cited by 67

Pandemic Preparedness and Response: Lessons From COVID-19

Fauci, A. S., & Folkers, G. K. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad095 · Cited by 62

Dealing with a mucosal viral pandemic: lessons from COVID-19 vaccines

Mouro, V., & Fischer, A. (2022) · Mucosal Immunology · doi:10.1038/s41385-022-00517-8 · Cited by 56

The immunopathogenesis of a cytokine storm: The key mechanisms underlying severe COVID-19

Hiti, L., Markovič, T., Lainščak, M., Farkaš, J., Pal, E., & Mlinarič‐Raščan, I. (2025) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2024.12.003 · Cited by 65

Antibody Titers and Protection against Omicron (BA.1 and BA.2) SARS-CoV-2 Infection

Dimeglio, C., Migueres, M., Bouzid, N., Chapuy‐Regaud, S., Gernigon, C., Da-Silva, I., Porcheron, M., Martin‐Blondel, G., Hérin, F., & Izopet, J. (2022) · Vaccines · doi:10.3390/vaccines10091548 · Cited by 45

A novel deep generative model for mRNA vaccine development: Designing 5′ UTRs with N1-methyl-pseudouridine modification

Tang, X., Huo, M., Chen, Y., Huang, H., Qin, S., Luo, J., Qin, Z., Jiang, X., Liu, Y., Duan, X., et al. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.11.003 · Cited by 47

Vaccine effectiveness against SARS-CoV-2 infection and severe outcomes among individuals with immune-mediated inflammatory diseases tested between March 1 and Nov 22, 2021, in Ontario, Canada: a population-based analysis

Widdifield, J., Kwong, J. C., Chen, S., Eder, L., Benchimol, E. I., Kaplan, G. G., Hitchon, C. A., Aviña-Zubieta, J. A., Lacaille, D. V., Chung, H., et al. (2022) · The Lancet Rheumatology · doi:10.1016/s2665-9913(22)00096-0 · Cited by 43

In Silico Studies to Support Vaccine Development

Saldanha, L., Langel, Ü., & Vale, N. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020654 · Cited by 41

Design and lyophilization of mRNA-encapsulating lipid nanoparticles

Wang, T., Yu, T., Li, W., Liu, Q., Sung, T., & Higuchi, A. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124514 · Cited by 42

Global safety monitoring of COVID-19 vaccines: how pharmacovigilance rose to the challenge

Rudolph, A., Mitchell, J., Barrett, J., Sköld, H., Taavola, H., Erlanson, N., Melgarejo-González, C., & Yue, Q. (2022) · Therapeutic Advances in Drug Safety · doi:10.1177/20420986221118972 · Cited by 46

Gramicidin S and melittin: potential anti-viral therapeutic peptides to treat SARS-CoV-2 infection

Enayathullah, M. G., Parekh, Y., Banu, S., Ram, S., Nagaraj, R., Kumar, B. K., & Idris, M. M. (2022) · Scientific Reports · doi:10.1038/s41598-022-07341-x · Cited by 42

Immune Response to SARS-CoV-2 Vaccines

Bellamkonda, N., Lambe, U. P., Sawant, S. A., Nandi, S. S., Chakraborty, C., & Shukla, D. (2022) · Biomedicines · doi:10.3390/biomedicines10071464 · Cited by 37

The quest for vaccine-induced immune correlates of protection against tuberculosis

Nemes, E., Fiore-Gartland, A. J., Boggiano, C., Coccia, M., D’Souza, P., Gilbert, P. B., Ginsberg, A. M., Hyrien, O., Laddy, D. J., Makar, K. W., et al. (2022) · Vaccine Insights · doi:10.18609/vac/2022.027 · Cited by 37

Impact of COVID-19 Pandemic on Tuberculosis Preventive Services and Their Post-Pandemic Recovery Strategies: A Rapid Review of Literature

Jeong, Y., & Min, J. (2023) · Journal of Korean Medical Science · doi:10.3346/jkms.2023.38.e43 · Cited by 35

pH-Sensitive and Biodegradable Mn3(PO4)2·3H2O Nanoparticles as an Adjuvant of Protein-Based Bivalent COVID-19 Vaccine to Induce Potent and Broad-Spectrum Immunity

Zhou, S., Zhang, R., You, Z.-W., Zou, Y.-K., Wen, Y., Wang, J., Ding, D., Bian, M.-M., Zhang, Z.-M., Yuan, H., et al. (2023) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c19736 · Cited by 34

The Impact of COVID-19 on RNA Therapeutics: A Surge in Lipid Nanoparticles and Alternative Delivery Systems

Parvin, N., Mandal, T. K., & Joo, S. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16111366 · Cited by 36

Elicitation of potent SARS-CoV-2 neutralizing antibody responses through immunization with a versatile adenovirus-inspired multimerization platform

Chevillard, C., Amen, A., Besson, S., Hannani, D., Bally, I., Dettling, V., Gout, E., Moreau, C., Buisson, M., Gallet, S., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.02.011 · Cited by 35

MPLA-Adjuvanted Liposomes Encapsulating S-Trimer or RBD or S1, but Not S-ECD, Elicit Robust Neutralization Against SARS-CoV-2 and Variants of Concern

Wang, J., Yin, X., Wen, Y., Lu, J. L., Zhang, R., Zhou, S., Liao, C.-M., Wei, H.-W., & Guo, J. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c02025 · Cited by 31

Innate Immune Response and Inflammasome Activation During SARS-CoV-2 Infection

Islamuddin, M., Mustfa, S. A., Ullah, S. N. M. N., Omer, U., Kato, K., & Parveen, S. (2022) · Inflammation · doi:10.1007/s10753-022-01651-y · Cited by 31

Analyzing the Systems Biology Effects of COVID-19 mRNA Vaccines to Assess Their Safety and Putative Side Effects

Hajjo, R., Sabbah, D. A., & Tropsha, A. (2022) · Pathogens · doi:10.3390/pathogens11070743 · Cited by 28

From Immunogen to COVID-19 vaccines: Prospects for the post-pandemic era

Miao, G., Chen, Z., Cao, H., Wu, W., Chu, X., Liu, H., Zhang, L., Zhu, H., Cai, H., Lu, X., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114208 · Cited by 27

Novel sialoglycan linkage for constructing adjuvant-protein conjugate as potent vaccine for COVID-19

Wen, Y., Zhang, R., Wang, J., Zhou, S., Peng, X., Ding, D., Zhang, Z.-M., Wei, H., & Guo, J. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.01.062 · Cited by 26

Recent Advances in the Molecular Design and Delivery Technology of mRNA for Vaccination Against Infectious Diseases

Lü, Y., Tang, L., Zhang, M., & Liu, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.896958 · Cited by 28

CMC Strategies and Advanced Technologies for Vaccine Development to Boost Acceleration and Pandemic Preparedness

Castellanos, M. M., Gressard, H., Li, X., Magagnoli, C., Moriconi, A., Stranges, D., Strodiot, L., Soto, M., Zwierzyna, M., & Campa, C. (2023) · Vaccines · doi:10.3390/vaccines11071153 · Cited by 28

RBD conjugate vaccine with a built-in TLR1/2 agonist is highly immunogenic against SARS-CoV-2 and variants of concern

Zhou, S., Zhang, R., Zhang, H.-W., Liu, Y., Wen, Y., Wang, J., Li, Y., You, Z.-W., Yin, X., Qiu, H. Y., et al. (2022) · Chemical Communications · doi:10.1039/d1cc06520c · Cited by 24

A comprehensive review on variants of SARS-CoVs-2: Challenges, solutions and open issues

Deepanshi, D., Budhiraja, I., Garg, D., Kumar, N., & Sharma, R. (2022) · Computer Communications · doi:10.1016/j.comcom.2022.10.013 · Cited by 24

Comparative antibody and cell-mediated immune responses, reactogenicity, and efficacy of homologous and heterologous boosting with CoronaVac and BNT162b2 (Cobovax): an open-label, randomised trial

Leung, N., Cheng, S. M. S., Cohen, C. A., Martín-Sánchez, M., Au, N. Y. M., Luk, L. L. H., Tsang, L. C. H., Kwan, K. K. H., Chaothai, S., Fung, L. W. C., et al. (2023) · The Lancet Microbe · doi:10.1016/s2666-5247(23)00216-1 · Cited by 27

A potent human monoclonal antibody with pan-neutralizing activities directly dislocates S trimer of SARS-CoV-2 through binding both up and down forms of RBD

Wang, X., Hu, A., Chen, X., Zhang, Y., Yu, F., Yue, S., Li, A., Zhang, J., Pan, Z., Yang, Y., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00954-8 · Cited by 23

Mutations in S2 subunit of SARS-CoV-2 Omicron spike strongly influence its conformation, fusogenicity, and neutralization sensitivity

Kumar, S., Delipan, R., Chakraborty, D., Kanjo, K., Singh, R., Singh, N., Siddiqui, S., Tyagi, A., Jha, V., Thakur, K. G., et al. (2023) · Journal of Virology · doi:10.1128/jvi.00922-23 · Cited by 23

Current Progress, Challenges and Prospects in the Development of COVID-19 Vaccines

Zhu, C., Pang, S., Liu, J., & Duan, Q. (2024) · Drugs · doi:10.1007/s40265-024-02013-8 · Cited by 24

CoVac501, a self-adjuvanting peptide vaccine conjugated with TLR7 agonists, against SARS-CoV-2 induces protective immunity

Long, Y., Sun, J., Song, T., Liu, T., Tang, F., Zhang, X., Ding, L., Miao, Y., Zhu, W., Pan, X., et al. (2022) · Cell Discovery · doi:10.1038/s41421-021-00370-2 · Cited by 22

A Novel 3-Gene Signature for Identifying COVID-19 Patients Based on Bioinformatics and Machine Learning

Lai, G., Liu, H., Deng, J., Li, K., & Xie, B. (2022) · Genes · doi:10.3390/genes13091602 · Cited by 22

SARS-CoV-2 infection and immune responses

Harne, R., Williams, B., Abdelaal, H. F. M., Baldwin, S. L., & Coler, R. N. (2023) · AIMS Microbiology · doi:10.3934/microbiol.2023015 · Cited by 21

Discovery of novel papain-like protease inhibitors for potential treatment of COVID-19

Hersi, F., Sebastian, A., Tarazi, H., Srinivasulu, V., Mostafa, A., Allayeh, A. K., Zeng, C., Hachim, I. Y., Liu, S., Abu‐Yousef, I. A., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115380 · Cited by 24

A novel Toxoplasma gondii TGGT1_316290 mRNA-LNP vaccine elicits protective immune response against toxoplasmosis in mice

Li, D., Zhang, Y., Li, S., & Zheng, B. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1145114 · Cited by 22

SARS-CoV-2 Omicron escapes mRNA vaccine booster-induced antibody neutralisation in patients with autoimmune rheumatic diseases: an observational cohort study

Kim, W.-J., Choi, S., Park, J. Y., Song, J. S., Chung, J.-W., & Choi, S. T. (2022) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2022-222689 · Cited by 20

The evolution of the global COVID-19 epidemic in Morocco and understanding the different therapeutic approaches of chitosan in the control of the pandemic

Hamdan, Y. A., Amerany, F. E., Desbrières, J., Aghrinane, A., Oudadesse, H., & Rhazi, M. (2022) · Polymer Bulletin · doi:10.1007/s00289-022-04579-3 · Cited by 22

Validation of an HPLC-CAD Method for Determination of Lipid Content in LNP-Encapsulated COVID-19 mRNA Vaccines

Yu, X., Yu, C., Wu, X., Cui, Y., Liu, X., Jin, Y., Li, Y., & Wang, L. (2023) · Vaccines · doi:10.3390/vaccines11050937 · Cited by 22

Bibliometric Analysis of Global Scientific Production on COVID-19 and Vaccines

Neto, A. R. D. S., de Carvalho, A. R. B., da Silva, M. D. F., Neta, M. M. R., Sena, I. V. D. O., Almeida, R. N., Filha, F. S. S. C., Silva, L. L. L. E., da Costa, G. R., Lira, I. M. D. S., et al. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20064796 · Cited by 20

Immunogenicity and In Vivo Protective Effects of Recombinant Nucleocapsid-Based SARS-CoV-2 Vaccine Convacell®

Rabdano, S. O., Ruzanova, E., Pletyukhina, I. V., Saveliev, N. S., Kryshen, K. L., Katelnikova, A. E., Beltyukov, P. P., Fakhretdinova, L. N., Safi, A., Rudakov, G. O., et al. (2023) · Vaccines · doi:10.3390/vaccines11040874 · Cited by 20

Prevention of a dengue outbreak via the large-scale deployment of Sterile Insect Technology in a Brazilian city: a prospective study

Poncio, L. D. C., dos Anjos, F. A., de Oliveira, D. A., da Rosa, A. D. O., Silva, B. P., Rebechi, D., Pedrosa, J. M., Franciscato, D. A. D. C., de Souza, C., & Paldi, N. (2023) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2023.100498 · Cited by 18

Serious adverse reaction associated with the COVID-19 vaccines of BNT162b2, Ad26.COV2.S, and mRNA-1273: Gaining insight through the VAERS

Yan, M., Zhao, H., Li, Z., Chow, J., Zhang, Q., Qi, Y.-P., Wu, S.-S., Zhong, M.-K., & Qiu, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.921760 · Cited by 18

Health-Promoting Behaviors among Older Adults with Noncommunicable Diseases in Rural and Urban Areas during the New Normal Post-COVID-19 Era: A Structural Equation Modeling Analysis

Suksatan, W., Teravecharoenchai, S., & Sarayuthpitak, J. (2022) · Nutrients · doi:10.3390/nu15010101 · Cited by 17

Geochemical Negative Emissions Technologies: Part II. Roadmap

Maesano, C. N., Campbell, J. S., Foteinis, S., Furey, V., Hawrot, O., Pike, D., Aeschlimann, S., Reginato, P., Goodwin, D., Looger, L. L., et al. (2022) · Frontiers in Climate · doi:10.3389/fclim.2022.945332 · Cited by 16

Cardiovascular Disease Complicating COVID-19 in the Elderly

Dayaramani, C., Leon, J. D., & Reiss, A. B. (2021) · Medicina · doi:10.3390/medicina57080833 · Cited by 16

The effect of COVID-19 vaccination on the menstrual pattern and mental health of the medical students: A mixed-methods study from a low and middle-income country

Kareem, R., Sethi, M. R., Inayat, S., & Irfan, M. (2022) · PLoS ONE · doi:10.1371/journal.pone.0277288 · Cited by 16

Stimulation of the immune system by a tumor antigen-bearing adenovirus-inspired VLP allows control of melanoma growth

Besson, S., Boucher, E., Laurin, D., Manches, O., Aspord, C., Hannani, D., & Fender, P. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.12.003 · Cited by 15

COVID-19 vaccine uptake and associated factors among adolescents and youths: Findings and implications for future vaccination programmes

Mudenda, S., Meyer, J. C., Fadare, J. O., Ogunleye, O. O., Saleem, Z., Matafwali, S. K., Daka, V., Chabalenge, B., Chama, J., Mukosha, M., et al. (2023) · PLOS Global Public Health · doi:10.1371/journal.pgph.0002385 · Cited by 15

A mathematical model of COVID-19 transmission

Jayatilaka, R., Patel, R., Brar, M., Tang, Y., Jisrawi, N., Chishtie, F., Drozd, J., & Valluri, S. R. (2021) · Materials Today Proceedings · doi:10.1016/j.matpr.2021.11.480 · Cited by 15

ALC-0315 Lipid-Based mRNA LNP Induces Stronger Cellular Immune Responses Postvaccination

Song, Z., Jin, L., Jiao, L., Yu, R., Liu, H., Zhang, S., Hu, Y., Sun, Y., Li, E., Zhao, G., et al. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00995 · Cited by 15

Immunization with a Prefusion SARS-CoV-2 Spike Protein Vaccine (RBMRNA-176) Protects against Viral Challenge in Mice and Nonhuman Primates

Ma, Q., Li, R., Guo, J., Li, M., Ma, L., Dai, J., Shi, Y., Dai, J., Huang, Y., Dai, C., et al. (2022) · Vaccines · doi:10.3390/vaccines10101698 · Cited by 13

Time to invest in cholera

Stout, R. C., Feasey, N., Péchayre, M., Thomson, N., & Chilima, B. Z. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.103044 · Cited by 14

Long-Term Immunity and Antibody Response: Challenges for Developing Efficient COVID-19 Vaccines

Sepand, M. R., Bigdelou, B., Ho, J. Q., Sharaf, M., Lannigan, A. J., Sullivan, I. M., da Silva, A. P., Barrett, L. O., McGoldrick, S., Lnu, Y., et al. (2022) · Antibodies · doi:10.3390/antib11020035 · Cited by 14

Development of lyophilized mRNA-LNPs with high stability and transfection efficiency in specific cells and tissues

Wang, T., Yu, T., Li, W., Chen, J., Cheng, S., Tian, Z., Sung, T., & Higuchi, A. (2025) · Regenerative Biomaterials · doi:10.1093/rb/rbaf023 · Cited by 15

Conservation and Evolution of Antigenic Determinants of SARS-CoV-2: An Insight for Immune Escape and Vaccine Design

Jaiswal, V., & Lee, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.832106 · Cited by 13

Development of a Modular NTA:His Tag Viral Vaccine for Co-delivery of Antigen and Adjuvant

Chung, Y. H., Volckaert, B. A., & Steinmetz, N. F. (2023) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.2c00601 · Cited by 13

COVID-19 Compulsory Vaccination and the European Court of Human Rights.

Vinceti, S. R. (2021) · Acta bio-medica dell'Ateneo parmense/Acta biomedica · doi:10.23750/abm.v92is6.12333 · Cited by 12

Rapid Identity and Quantity CQA Test for Multivalent mRNA Drug Product Formulations

Gao, R. Y., Riley, C. M., Toth, E., Blair, R. H., Gerold, M. N., McCormick, C., Taylor, A. W., Hu, T., Rowlen, K. L., & Dawson, E. D. (2022) · Vaccines · doi:10.3390/vaccines10101704 · Cited by 12

Race-ethnicity and COVID-19 Vaccination Beliefs and Intentions: A Cross-Sectional Study among the General Population in the San Francisco Bay Area

Weng, Y., Lu, D., Bollyky, J., Jain, V., Desai, M., Lindan, C., Boothroyd, D. B., Judson, T. J., Doernberg, S. B., Holubar, M. K., et al. (2021) · Vaccines · doi:10.3390/vaccines9121406 · Cited by 12

S100A4 exerts robust mucosal adjuvant activity for co-administered antigens in mice

Chaudhuri, A. S., Yeh, Y., Zewdie, O., Li, N. S., Sun, J., Jin, T., Wei, B., Holmgren, J. R., & Xiang, Z. (2022) · Mucosal Immunology · doi:10.1038/s41385-022-00535-6 · Cited by 12

A proteomic perspective and involvement of cytokines in SARS-CoV-2 infection

Banu, S., Idris, M. M., & Nagaraj, R. (2023) · PLoS ONE · doi:10.1371/journal.pone.0279998 · Cited by 11

A heterologous AZD1222 priming and BNT162b2 boosting regimen more efficiently elicits neutralizing antibodies, but not memory T cells, than the homologous BNT162b2 regimen

Baek, Y. J., Kim, W., Ko, J., Lee, Y.-J., Ahn, J. Y., Kim, J. H., Jang, H. C., Jeong, H. W., Kim, Y. C., Park, Y. S., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.01.063 · Cited by 11

Coding Therapeutic Nucleic Acids from Recombinant Proteins to Next-Generation Vaccines: Current Uses, Limitations, and Future Horizons

Harisa, G. I., Faris, T. M., Sherif, A. Y., Alzhrani, R. F., Alanazi, S. A., Kohaf, N. A., & Alanazi, F. K. (2023) · Molecular Biotechnology · doi:10.1007/s12033-023-00821-z · Cited by 11

Potential therapeutic effect of Shufeng Jiedu capsule and its major herbs on coronavirus disease 2019 (COVID-19): A review

Xu, Y., Li, Y., Wang, L., & Chen, F. (2021) · Drug Discoveries & Therapeutics · doi:10.5582/ddt.2021.01099 · Cited by 11

Getting to the (germinal) center of humoral immune responses to SARS-CoV-2

Tangye, S. G., Burnett, D. L., & Bull, R. A. (2022) · Cell · doi:10.1016/j.cell.2022.02.018 · Cited by 11

Working towards the development of vaccines and chemotherapeutics against neosporosis—With all of its ups and downs—Looking ahead

Imhof, D., Hänggeli, K. P. A., de Sousa, M. C. F., Vigneswaran, A., Hofmann, L., Amdouni, Y., Boubaker, G., Müller, J., & Hemphill, A. F. (2024) · Advances in Parasitology/Advances in parasitology · doi:10.1016/bs.apar.2024.01.001 · Cited by 10

Preclinical assessment of a recombinant RBD-Fc fusion protein as SARS-CoV-2 candidate vaccine

Dashti, N., Golsaz‐Shirazi, F., Soltanghoraee, H., Zarnani, A., Mohammadi, M., Imani, D., Jeddi‐Tehrani, M., Amiri, M. M., & Shokri, F. (2024) · European Journal of Microbiology and Immunology · doi:10.1556/1886.2024.00045 · Cited by 10

Development of T cell antigen-based human coronavirus vaccines against nAb-escaping SARS-CoV-2 variants

Zhou, H., Leng, P., Wang, Y., Yang, K., Li, C., Ojcius, D. M., Wang, P., & Jiang, S. (2024) · 中国科学通报：英文版 · doi:10.1016/j.scib.2024.02.041 · Cited by 10

Nasal irrigation efficiently attenuates SARS-CoV-2 Omicron infection, transmission and lung injury in the Syrian hamster model

Yuan, L., Zhu, H., Zhou, M., Ma, J., Liu, X., Wu, K., Ye, J., Yu, H., Chen, P., Chen, R., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105475 · Cited by 10

Effect of religious fatalism and concern about new variants on the acceptance of COVID-19 vaccines

Mamani-Benito, O. J., Farfán-Solís, R., Huayta-Meza, M. E., Tito-Betancur, M., Morales-García, W. C., & Tarqui, E. E. A. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1071543 · Cited by 10

New Anticancer Drugs: Reliably Assessing “Value” While Addressing High Prices

Stewart, D. J., Bradford, J., Sehdev, S. R., Ramsay, T., Navani, V., Rawson, N. S. B., Jiang, D., Gotfrit, J., Wheatley‐Price, P., Liu, G., et al. (2024) · Current Oncology · doi:10.3390/curroncol31050184 · Cited by 10

An elephant in the glasshouse? Trade-offs between acceleration and transformation in COVID-19 vaccine innovation policies

van de Burgwal, L., de Valk, T., Kempter, H., Gadau, M., Stubbs, D., & Boon, W. (2023) · Environmental Innovation and Societal Transitions · doi:10.1016/j.eist.2023.100736 · Cited by 9

Vaccines for Global Health: Progress and Challenges

Knisely, J. M., & Erbelding, E. J. (2024) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiae511 · Cited by 9

Monitoring Immune Responses to Vaccination: A Focus on Single-Cell Analysis and Associated Challenges

Montgomery, L. C., & Larbi, A. (2025) · Vaccines · doi:10.3390/vaccines13040420 · Cited by 9

Spike-specific IgG4 generated post BNT162b2 mRNA vaccination is inhibitory when directly competing with functional IgG subclasses

Tam, J. C. H., Sibayan, A. C., Seow, J., Graham, C., Kurshan, A., Merrick, B., Stanton, R. J., & Doores, K. J. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116000 · Cited by 12

Real-time monitoring of SARS-CoV-2 evolution during the COVID-19 pandemic

Korber, B., Fischer, W., & Theiler, J. P. (2025) · Cell Host & Microbe · doi:10.1016/j.chom.2025.10.013 · Cited by 8

mRNA-Based Therapeutics: Advances in Drug Delivery, Comparative Innovations, and Biomedical Applications

Joshi, R., Sharma, S., Kapoor, D. U., Prajapati, B. G., Huanbutta, K., & Sriamornsak, P. (2026) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c00774 · Cited by 10

In Silico Screening of Novel TMPRSS2 Inhibitors for Treatment of COVID-19

Wang, S., Fang, X., & Wang, Y. (2022) · Molecules · doi:10.3390/molecules27134210 · Cited by 9

Multi-phasic gene profiling using candidate gene approach predict the capacity of specific antibody production and maintenance following COVID-19 vaccination in Japanese population

Takemoto, Y., Tanimine, N., Yoshinaka, H., Tanaka, Y., Takafuta, T., Sugiyama, A., Tanaka, J., & Ohdan, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1217206 · Cited by 9

Metabolic and toxicological considerations regarding CGRP mAbs and CGRP antagonists to treat migraine in COVID-19 patients: a narrative review

Takizawa, T., Ihara, K., Uno, S., Ohtani, S., Watanabe, N., Imai, N., Nakahara, J., Hori, S., García‐Azorín, D., & Martelletti, P. (2023) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2023.2280221 · Cited by 9

U.S. COVID-19 vaccine distribution strategies, systems, performance, and lessons learned, December 2020 – May 2023

Duggar, C., Santoli, J. M., Noblit, C., Moore, L. B., Kalach, R. E., & Bridges, C. B. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.02.020 · Cited by 9

Towards developing multistrain PEDV vaccines: Integrating basic concepts and SARS-CoV-2 pan-sarbecovirus strategies

Fragoso-Saavedra, M., & Liu, Q. (2025) · Virology · doi:10.1016/j.virol.2025.110412 · Cited by 10

Determinants of COVID-19 vaccine acceptance in Mozambique: The role of institutional trust

Hu, B., Yang, W. Y. L., Bouanchaud, P., Chongo, Y., Wheeler, J., Chicumbe, S., & Chissano, M. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.03.053 · Cited by 8

Review of pediatric emergency care and the COVID‐19 pandemic

Foster, A. A., Walls, T. A., Alade, K. H., Brown, K., Gausche‐Hill, M., Lin, S., Rose, E., Ruttan, T. K., Shahid, S., Sorrentino, A., et al. (2023) · Journal of the American College of Emergency Physicians Open · doi:10.1002/emp2.13073 · Cited by 7

Double trouble: COVID-19 vaccine misinformation amidst conflict in Ukraine

Tharwani, Z. H., Ennab, F., Matiashova, L., Nawaz, F. A., Volkova, A., Trill, V., & Essar, M. Y. (2022) · Annals of Medicine and Surgery · doi:10.1016/j.amsu.2022.104127 · Cited by 8

Protein-Protein Conjugation Enhances Immunogenicity of SARS-CoV-2 Receptor Binding Domain (RBD) Vaccines

Scaria, P. V., Rowe, C. G., Chen, B. B., Dickey, T. H., Renn, J. P., Lambert, L., Barnafo, E. K., Rausch, K. M., Tolia, N. H., & Duffy, P. E. (2022) · iScience · doi:10.1016/j.isci.2022.104739 · Cited by 9

Safety and Immunogenicity of a Modified Self-Amplifying Ribonucleic Acid (saRNA) Vaccine Encoding SARS-CoV-2 Spike Glycoprotein in SARS-CoV-2 Seronegative and Seropositive Ugandan Individuals

Kitonsa, J., Serwanga, J., Abaasa, A., Lunkuse, J. F., Cheeseman, H. M., Ruzagira, E., Kato, L., Nambaziira, F., Oluka, G. K., Gombe, B., et al. (2025) · Vaccines · doi:10.3390/vaccines13060553 · Cited by 8

Accelerating clinical trial development in vaccinology: COVID-19 and beyond

Corey, L., & Miner, M. D. (2022) · Current Opinion in Immunology · doi:10.1016/j.coi.2022.102206 · Cited by 17

Effect of coronavirus disease 2019 on the vaccine development paradigm

Okay, S. (2023) · Exploration of Immunology · doi:10.37349/ei.2023.00111 · Cited by 5

How New Models Of Vaccine Development For COVID-19 Have Helped Address An Epic Public Health Crisis

Bloom, D. E., Cadarette, D., Ferranna, M., Hyer, R. N., & Tortorice, D. L. (2021) · Health Affairs · doi:10.1377/hlthaff.2020.02012 · Cited by 68

Super-rapid race for saving lives by developing COVID-19 vaccines

Uttarilli, A., Amalakanti, S., Kommoju, P.-R., Sharma, S., Goyal, P., Manjunath, G. K., Upadhayay, V., Parveen, A., Tandon, R., Prasad, K. S., et al. (2021) · Berichte aus der medizinischen Informatik und Bioinformatik/Journal of integrative bioinformatics · doi:10.1515/jib-2021-0002 · Cited by 31

Looking beyond the origin of SARS-CoV-2: Significant strategic aspects during the five-year journey of COVID-19 vaccine development

Chakraborty, C., Lo, Y.-H., Bhattacharya, M., Das, A., & Wen, Z. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102527 · Cited by 8